Quick Answer
Ensysce Biosciences, Inc. reported Stockholders Equity of $3.21 million for fiscal year 2025.
Ensysce Biosciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $3.21M | -13.3% |
| 2024 | $3.71M | +1248.6% |
| 2023 | -$322.9K | +91.3% |
| 2022 | -$3.71M | +52.9% |
| 2021 | -$7.88M | -22.3% |
| 2020 | -$6.44M | -228.8% |
| 2019 | $5.00M | +0.0% |
| 2018 | $5.00M | +0.0% |
| 2017 | $5.00M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.20M | -82.6% | -64.5% |
| June 30, 2025 | $3.39M | +87.5% | +11.2% |
| March 31, 2025 | $3.05M | -18.7% | -17.8% |
| December 31, 2024 | $3.71M | +1248.6% | -46.3% |
| September 30, 2024 | $6.91M | +365.2% | +282.1% |
| June 30, 2024 | $1.81M | -56.1% | -51.8% |
| March 31, 2024 | $3.75M | +2148.7% | +1261.2% |
| December 31, 2023 | -$322.9K | +91.3% | -121.7% |
- Ensysce Biosciences, Inc. showed a decrease of -13.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, Ensysce Biosciences, Inc.’s stockholders equity has declined by 35.7% (from $5.00 million to $3.21 million).
- The most recent figure is from Ensysce Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: